| (Values in U.S. Thousands) | Sep, 2017 | Jun, 2017 | Mar, 2017 | Dec, 2016 | Sep, 2016 |
| Sales | -9,999,000 | 10,050 | 9,840 | 4,910 | 7,340 |
| Sales Growth | -99,592.53% | +2.13% | +100.41% | -33.11% | +52.92% |
| Net Income | -9,999,000 | -109,820 | -90,400 | -84,930 | -73,950 |
| Net Income Growth | -9,004.90% | -21.48% | -6.44% | -14.85% | -15.06% |
Kite Pharma Inc
(KITE)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of cancer immunotherapy products. The Company is developing a pipeline of eACT-based product candidates for the treatment of solid and hematological malignancies. Kite Pharma, Inc. is headquartered in Santa Monica, California.
Fiscal Year End Date: 12/31